Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study

Documenti analoghi

• Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia not Adequately Controlled with Current Lipid-Lowering Therapy: Design and Rationale of the ODYSSEY FH Studies
  di: Kastelein, John J. P., et al.
  Pubblicazione: (2014)
• Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher
  di: Ginsberg, Henry N., et al.
  Pubblicazione: (2016)
• ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia
  di: Kastelein, John J.P., et al.
  Pubblicazione: (2015)
• Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia
  di: Ginsberg, Henry N., et al.
  Pubblicazione: (2019)
• Efficacy and Safety of Alirocumab in Individuals with Diabetes Mellitus: Pooled Analyses from Five Placebo-Controlled Phase 3 Studies
  di: Ginsberg, Henry N., et al.
  Pubblicazione: (2018)